10928 results for 'rawl replac bind protein 4'

Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including

Cell Signalling · MetabolismThe mTOR Signalling PathwaymTOR is a master regulator of cell growth, metabolism and survival, integrating nutrient, growth-factor and energy signals through two comp

Annexin V Apoptosis Assay Kits | Flow Cytometry Detection | Assay Genie

Tocilizumab (Actemra®) in COVID-19 Treatment What is Tocilizumab? Tocilizumab, also called atlizumab, is an immunosuppress

Quick Facts About AducanumabWhat is Aducanumab?Aducanumab is a monoclonal antibody designed to target and reduce amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease.What

Pancreatic cancer survival rates Despite recent advances in our understanding of this disease, pancreatic cancer is one of the world’s most lethal malignan

Polo-like kinase (Plk1) Polo-like kinase (Plk1), is a serine/threonine kinase that is active during mitosis (Hamanaka et al., 1995). Its name is derived from its origi

Interleukin 12 in COVID-19 Prophylactics Interleukin 12 is a cytokine with wide-reaching effects in the innate and adaptive immune system. Of

Cell Death · BiomarkersCleaved Caspase-3: Activation, Function and Detection in ApoptosisCaspase-3 sits at the point where apoptotic signalling becomes irreversible. It is made as an inactive proenzym

What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a

Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem

Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does

What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas

Low-dose IL-2 expands regulatory T cells. High-dose IL-2 expands the cells they exist to restrain. Same cytokine, same receptor family, opposite clinical intent — and the explanation is a receptor su

A chimeric antigen receptor is a synthetic protein wired into a real signalling pathway. The extracellular half is an antibody fragment; everything below the membrane is borrowed from the T-cell rece

Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By

Anti-angiogenic therapy does not work by starving tumours, and the trials that assumed it did are the reason the field spent a decade disappointed. Cutting off the blood supply was the original pitch

Quick Facts About BococizumabWhat is Bococizumab?Bococizumab is a monoclonal antibody that targets PCSK9, a protein involved in cholesterol regulation.How Does Bococizumab Work?It inhibi